These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14687168)

  • 1. A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centres.
    Jensen DM; Cotler SJ; Lam H; Harb G; Shillington A
    Aliment Pharmacol Ther; 2004 Jan; 19(1):69-77. PubMed ID: 14687168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescribing practices for the treatment of hepatitis C in a Veterans Affairs medical center.
    Mangin EF; Jones WN
    Am J Health Syst Pharm; 2004 Jul; 61(14):1479-82. PubMed ID: 15332696
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictors of response of US veterans to treatment for the hepatitis C virus.
    Backus LI; Boothroyd DB; Phillips BR; Mole LA
    Hepatology; 2007 Jul; 46(1):37-47. PubMed ID: 17567830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study.
    Ide K; Sato I; Imai T; Hawke P; Yamada H; Kawasaki Y; Masaki N
    Biol Pharm Bull; 2016 Dec; 39(12):2060-2065. PubMed ID: 27645378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence with hepatitis C therapy in the Department of Veterans Affairs.
    Iqbal SU; Cunningham F; Lee A; Miller DR; Li NC; Cheung R; Kazis L
    J Clin Pharm Ther; 2008 Jun; 33(3):251-61. PubMed ID: 18452412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System.
    Yeh WS; Armstrong EP; Skrepnek GH; Malone DC
    Pharmacotherapy; 2007 Jun; 27(6):813-24. PubMed ID: 17542764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators.
    Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Pellicelli A; Grisorio B; Barbarini G
    J Hepatol; 2000 Sep; 33(3):448-55. PubMed ID: 11020001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment and utilization of rapid virologic response in US veterans with chronic hepatitis C: evaluating provider adherence to practice guidelines.
    Hwang EW; Thomas IC; Cheung R; Backus LI
    J Clin Gastroenterol; 2013 Mar; 47(3):264-70. PubMed ID: 23269309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
    Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin.
    Tang S; Cheng IK; Leung VK; Kuok UI; Tang AW; Wing Ho Y; Neng Lai K; Mao Chan T
    J Hepatol; 2003 Nov; 39(5):875-8. PubMed ID: 14568274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
    N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels.
    Bini EJ; Mehandru S
    Aliment Pharmacol Ther; 2006 Mar; 23(6):777-85. PubMed ID: 16556180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment.
    Kogure T; Ueno Y; Fukushima K; Nagasaki F; Inoue J; Kakazu E; Matsuda Y; Kido O; Nakagome Y; Kimura O; Obara N; Wakui Y; Iwasaki T; Shimosegawa T
    World J Gastroenterol; 2007 Aug; 13(32):4394-7. PubMed ID: 17708618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
    Nordstrom EM; Keniston A; Baouchi F; Martinez-Camacho A
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up].
    Seydi M; Morlat P; Bonnet F; Rambeloarisoa J; Bernard N; Lacoste D; Bonarek M; Trimoulet P; Ramanampamonjy R; Lafon ME; Dramé M; Beylot J
    Rev Med Interne; 2005 Apr; 26(4):280-7. PubMed ID: 15820563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia.
    Calleja JL; Albillos A; Moreno-Otero R; Rossi I; Cacho G; Domper F; Yebra M; Escartín P
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1179-86. PubMed ID: 10468699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment laparoscopic appearance of the liver can predict response to combination therapy with interferon alpha 2B and ribavirin in chronic hepatitis C.
    Bajaj JS; Molina E; Regev A; Schiff ER; Jeffers LJ
    Gastrointest Endosc; 2003 Sep; 58(3):380-3. PubMed ID: 14528212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience.
    Schvarcz R; Ando Y; Sönnerborg A; Weiland O
    J Hepatol; 1995; 23 Suppl 2():17-21. PubMed ID: 8720289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.